PTC Therapeutics: exec. vp and clo Mark Boulding exercised 2,073 shares

What happened

• Mark Boulding, executive vice president and chief legal officer, exercised options for 2,073 shares at $39.42 per share (total cost $81,718) on Oct 5 and Oct 6, 2026, and sold 2,073 shares in open-market transactions for total proceeds of $132,791.
• The filing also reports derivative dispositions of 1,638 shares on Oct 5, 2026 and 435 shares on Oct 6, 2026 at $0.00.

Key details

• Transaction dates and prices:
  • Oct 5, 2026: exercised 1,638 shares at $39.42 (acquired $64,570); sold 1,638 shares at weighted average $64.03 for $104,881. (F2: sale prices ranged $64.00 to $64.34.)
  • Oct 6, 2026: exercised 435 shares at $39.42 (acquired $17,148); sold 435 shares at weighted average $64.16 for $27,910. (F3: sale prices ranged $64.00 to $64.90.)
  • Derivative dispositions reported at $0.00 for 1,638 shares (Oct 5, 2026) and 435 shares (Oct 6, 2026).
• Shares owned after the transactions: not reported in the provided filing.
• Relevant footnotes:
  • F1: transactions were effected under a written Rule 10b5-1 plan adopted Sep 10, 2025.
  • F2/F3: weighted-average sale prices reflect multiple trades; reporting person will provide breakdown on request.
  • F4: the option was granted Jan 5, 2023 and vests over four years with the schedule described in the filing.
• Filing date and timeliness: report filed Oct 7, 2026 (period of report Oct 5, 2026); filing does not indicate lateness.

Why it may matter

• The filing shows options were exercised and the resulting shares were sold in open-market transactions on Oct 5-6, 2026 (the exercised shares were disposed after exercise).
• The sales were executed under a written Rule 10b5-1 trading plan, per the filing.
• This filing does not show why the insider traded or why the company acted.